3 Biotech Stocks That Skyrocketed This Week: Can They Go Higher?
Every biotech company goes into a clinical study with great hopes -- and often great fears, as well. There's no guarantee that all will go well. All the time and money poured into an experimental drug can go down the drain with bad results. But good results mean an entirely different story.
Three biotechs especially felt the thrill of good clinical results over the past week: Insmed (NASDAQ: INSM), Newlink Genetics (NASDAQ: NLNK), and Voyager Therapeutics (NASDAQ: VYGR). All three stocks skyrocketed, with two of them pretty much going into orbit. Here's why Insmed, Newlink Genetics, and Voyager had such great weeks -- and what their chances could be for keeping the momentum going.
Image source: Getty Images.
Source: Fool.com
Merck & Co. Inc. Aktie
Die Merck & Co. Inc. Aktie steht gut da: Deutlich mehr Buy- als Sell-Einschätzungen in der Community.
Ein Kursziel von 125 € für Merck & Co. Inc. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 106.4 €.